Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C9H7N7O2S
Numéro CAS:
Poids moléculaire :
277.26
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
EC Number:
207-175-4
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
Azathioprine, ≥98%
biological source
synthetic (organic)
Quality Level
assay
≥98%
form
powder
solubility
1 M NH4OH: 20 mg/mL, clear to slightly hazy
storage temp.
−20°C
SMILES string
Cn1cnc(c1Sc2ncnc3[nH]cnc23)[N+]([O-])=O
InChI
1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)
InChI key
LMEKQMALGUDUQG-UHFFFAOYSA-N
Gene Information
human ... PPAT(5471)
Biochem/physiol Actions
Has shown promise in treatment of alopecia areata (autoimmune hair loss), with no difference in effectiveness between genders.
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Carc. 1B - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Classe de stockage
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Susan Farshi et al.
International journal of dermatology, 49(10), 1188-1193 (2010-10-05)
Alopecia areata is an autoimmune disease resulting in partial or total nonscarring hair loss and the treatment of severe alopecia areata is difficult. The aim of this study was to evaluate the efficacy and safety of azathioprine as a systemic
Joanna Kitley et al.
Journal of neurology, neurosurgery, and psychiatry, 84(8), 918-921 (2013-03-08)
Neuromyelitis optica (NMO) is a severe autoimmune inflammatory disorder associated with considerable relapse-related disability. Immunosuppression is the mainstay of treatment but many patients do not tolerate first-line immunosuppressive agents, or experience ongoing relapses. To evaluate the effectiveness and tolerability of
Laurent Peyrin-Biroulet et al.
Gut, 63(1), 88-95 (2013-08-27)
The Crohn's Disease Activity Index (CDAI) has been criticised due to heavy weighting on subjective clinical symptoms. C-reactive protein (CRP) and endoscopic lesions are objective measures of inflammation. We investigated the relationships between clinical disease activity, CRP normalisation and mucosal
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| A4638-1G | 04061833374801 |

